Stemline Therapeutics Культура компании

Dr. Eric K. Rowinsky, M.D. serves as the Chief Scientific Officer of Oncology at Clear Path Development Company, a biotechnology company that partners with leading biopharmaceutical companies to expand early product pipeline opportunities and minimize financial impact. Dr. Rowinsky serves as the President of Rgenix, Inc. Dr. Rowinsky serves as Chief Medical Officer of Mitra Biotech Pvt Ltd. He has been Consultant of Stemline Therapeutics, Inc. since October 27, 2015. Dr. Rowinsky served as a Consultant of Fortress Biotech, Inc. since October 2010. He serves as Consultant/Scientific Advisor to multiple biotech and pharmaceutical companies in cancer drug development. He has been an Independent Consultant since January 2010. He has been Strategic Advisor for Oncology Product Development at RRD International, LLC since March 2010 and oversees oncology product development. Dr. Rowinsky served as the Chief Medical Officer, Head of Research & Development and Executive Vice President at Stemline Therapeutics, Inc. from January 09, 2012 to October 27, 2015. He served as the Chief Medical Officer and Scientific Advisor of Champions Biotechnology, Inc. (now Champions Oncology, Inc.). Dr. Rowinsky was Founder of Primrose Therapeutics (acquired by Kadmon Therapeutics Inc.) and served as its Chief Executive Officer. Dr. Rowinsky served as a Scientific Advisor to ImClone Systems Corporation. He has over 25 of research and drug development experience, oncology expertise and broad scientific and medical knowledge. He served as Chief Medical Officer of ImClone Systems Corporation from February 21, 2005 to 2007 and served as its Executive Vice President of Clinical Development and Regulatory Affairs from December 2007 to 2009. He served as Executive Vice President of ImClone Systems Corporation since December 2007 and served as its Chief Medical Officer. He was Senior Vice President of Clinical Research at ImClone Systems LLC from February 21, 2005 to December 2007 and its Chief Medical Officer since February 21, 2005 and Executive Vice President since December 2007. Dr. Rowinsky served as Senior Vice President of Clinical Research at ImClone Systems Corporation from February 21, 2005 to December 2007. He joined ImClone in 2005. He served as Chief Medical Officer of Lilly/CTRC and JHMI. He served as Scientific Advisor at Champions Oncology, Inc. From 1996 to 2010, he served as a Director of the Institute of Drug Development of the Cancer Therapy and Research Center in San Antonio, Texas. He served as Director of Clinical Research and SBC Endowed Chairman for Early Drug Development at the IDD of the Cancer Therapy and Research Centre in San Antonio, Texas. He served on active staff at the Johns Hopkins School of Medicine from 1987 to 1996. He has been Executive Chairman of Rgenix, Inc. since December 7, 2015 and its Director since November 9, 2015. He has been Chairman of Clinical Advisory Board at Rgenix, Inc. since November 9, 2015. He serves as the Chairman of Clinical Advisory Board at OncoVista Innovative Therapies, Inc. He has been Chairman of Navidea Biopharmaceuticals, Inc. since September 22, 2016. He serves as the Chairman of the Scientific Advisory Board at Navidea Biopharmaceuticals, Inc. and BioTheryX, Inc. He served as the Chairman of Clinical Advisory Board at Aviation Upgrade Technologies Inc. He serves as Co-Vice Chairman of the Board at Fortress Biotech, Inc. and served as its Vice Chairman since October 2010. Dr. Rowinsky has been a Director of Navidea Biopharmaceuticals, Inc since July 16, 2010 and BIND Therapeutics, Inc. since September 2014. He has been Director of Verastem, Inc. since May 3, 2017. He has been Director of BioXcel Corporation since January 5, 2017. He has been an Independent Director of Biogen Inc. since March 2010. He serves as a Director of Immunexcite, Inc. and DLVR Therapeutics Inc. He serves on numerous scientific and oncology advisory boards for biotechnology and pharmaceutical companies. He serves as Member of Clinical Advisory Board at Supratek Pharma Inc. He serves as Member of Scientific Advisory Board at OncoVista Innovative Therapies, Inc. Dr. Rowinsky served as a Member of Oncology Clinical Advisory Board at Mirati Therapeutics, Inc. He served as a Member of Scientific Advisory Board at Mitra Biotech Pvt Ltd since February 18, 2015. He was Member of Clinical Advisory Board at TetraLogic Pharmaceuticals Corporation. He served as a Member of SP1049 & SP-MET-X1 Clinical Advisory Board at Supratek Pharma Inc. He served as Member of the Scientific Advisory Board at SignPath Pharma Inc. He served as a Director of DNIB Unwind, Inc. since September 2014. He served as a Director of ImClone Systems Corporation from 2005 to November 2008. He served as a Director of Tapestry Pharmaceuticals, Inc. from December 2007 to March 3, 2008 and Mast Therapeutics, Inc. from February 25, 2008 to June 15, 2011. He served as a Member of the Oncology Scientific Advisory Board at Tapestry Pharmaceuticals, Inc. since April 27, 2004. Dr. Rowinsky served as a Member of Clinical Advisory Board at Point Therapeutics Inc., since June 2004. He is an Editor-in-Chief of Investigational New Drugs and an Associate Editor of Cancer Research, Clinical Cancer Research, Annals of Oncology and several other oncology journals. He has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. He serves on the Board of Scientific Counselors of the National Cancer Institute. He is a Member of the NCI Board of Scientific Counselors. He represented the AACR as Co-chairman of the scientific committee of the 16 th EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Geneva, Switzerland. Dr. Rowinsky serves as an Adjunct Professor of Medicine at New York University School of Medicine. He served as Clinical Professor of Medicine (Division of Medical Oncology) at the University of Texas Health Science Center, San Antonio (UTHSCSA), Texas, Institute from 1996 to 2006. He was an Associate Professor of Oncology at Johns Hopkins School of Medicine from 1987 to 1996. He served on the faculty of the Department of Oncology at Johns Hopkins University School of Medicine since 1996. He was a NCI Principal Investigator on U01 anticancer drug development grants. He has done work on the development of paclitaxel, docetaxel, topotecan, irinotecan, erlotinib and gefitinib among others. Dr. Rowinsky has published over 230 papers and remains actively involved in preclinical and clinical research. Among, his honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. Following his residency in Internal Medicine from University of California, San Diego, he completed fellowship training in medical oncology at the Johns Hopkins University School of Medicine. Dr. Rowinsky holds BA degree from New York Unive

Mr. David G. Gionco has been the Chief Accounting Officer and Vice President of Finance at Stemline Therapeutics, Inc. since December 16, 2013 and since January 16, 2014 respectively. Mr. Gionco served as Chief Accounting Officer and Group Vice President of Savient Pharmaceuticals, Inc., since May 29, 2012 and served as its Treasurer since May 29, 2012. He served as Group Vice President of Finance at Savient Pharmaceuticals, Inc. He served as the Chief Financial Officer, Vice President and Treasurer of Savient Pharmaceuticals Inc., from February 2009 to September 12, 2011. He has more than 30 years of experience in corporate finance, including 23 years in senior financial functions at both multi-national pharmaceutical companies and development-stage biotechnology firms. Mr. Gionco served as Vice President of Corporate Finance and Controller of Savient. Through his career, he has held various audit, corporate accounting, financial planning, finance and controller roles of increasing responsibility at companies including Medco, Merck & Co., Progenics Pharmaceuticals, Inc. and Odyssey Pharmaceuticals, Inc., where he served as Acting Chief Financial Officer/Director of Finance and Controller before joining Savient. He has 7 years of financial auditing experience with a major public accounting firm. He is also a Certified Public Accountant in New York State. Mr. Gionco holds a B.S. in Accounting from Fairleigh Dickinson University and an MBA in Finance from Rutgers University.

Mr. Kenneth Hoberman has been the Chief Operating Officer of Stemline Therapeutics, Inc., since March 25, 2013 and serves as its Corporate Secretary. Mr. Hoberman served as Vice President of Operations at Stemline Therapeutics, Inc., from March 2012 to March 2013. He served as the Head of Corporate Development at Stemline Therapeutics, Inc. He was a Consultant to Stemline since its founding in 2003. He served as Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc. He founded and served as Head of Business Development of Access Oncology, Inc. and was a key member of the transition team that led the acquisition of Access Oncology, Inc. by Keryx. He served as Managing Director at Hawkins BioVentures. He has been a Director of TG Therapeutics, Inc., since December 17, 2014. Mr. Hoberman received a B.S.B.A. degree in Finance from Boston University and completed post-baccalaureate studies at Columbia University.

Robert Francomano serves as the Senior Vice President, Global Head of Commercial of Stemline Therapeutics, Inc.. Robert currently resides in the Greater Philadelphia Area.

John Salvagno serves as the Sr. Vice President Quality Operations of Stemline Therapeutics, Inc.. John currently resides in the Greater New York City Area.

Peter McDonald serves as the Sr. VP, Corporate and Business Development of Stemline Therapeutics, Inc.. Peter currently resides in the Greater New York City Area.

Enrique Poradosu serves as the SVP Business & Scientific Strategy of Stemline Therapeutics, Inc.. Enrique currently resides in the Greater Boston Area.

David Gionco serves as the Vice President of Finance and Chief Accounting Officer of Stemline Therapeutics, Inc.. David currently resides in the Greater New York City Area.